首页> Transplant international :> CIRRUS I - STUDY: EVALUATION OF EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-CD40 ANTIBODY ISCALIMAB (CFZ533) IN RENAL TRANSPLANT RECIPIENTS - STUDY RATIONALE AND DESIGN

CIRRUS I - STUDY: EVALUATION OF EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-CD40 ANTIBODY ISCALIMAB (CFZ533) IN RENAL TRANSPLANT RECIPIENTS - STUDY RATIONALE AND DESIGN

导出原文传递

翻译打印收藏纠错

作者： Thaiss, F. ^[1] ; Vincenti, F. ^[2] ; Citterio, F. ^[3] ; Martzloff, E. -D. ; Espie, P. ; Speziale, A. ; Hessel, K. ; Oppenheimer, F.

作者单位： Novartis Pharma GmbH, Nurnberg, Germany ^[1] CIRRUS I Study Grp, Basel, Switzerland ^[2] Novartis Pharma AG, Basel, Switzerland ^[3]

发布时间 2020-08-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

Transplant international

2019年32卷S3期

45-45页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览3

点击下载本期目录封面

Transplant international

2019年32卷S3期

45-45页

检索历史清除

CIRRUS I - STUDY: EVALUATION OF EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-CD40 ANTIBODY ISCALIMAB (CFZ533) IN RENAL TRANSPLANT RECIPIENTS - STUDY RATIONALE AND DESIGN

Transplant international

相似文献

Transplant international

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CIRRUS I - STUDY: EVALUATION OF EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI-CD40 ANTIBODY ISCALIMAB (CFZ533) IN RENAL TRANSPLANT RECIPIENTS - STUDY RATIONALE AND DESIGN

Transplant international

相似文献

Transplant international

相关期刊

检索历史清除